About ABBV-744 as a potential therapeutic option for aggressive cancers
In Segment C, individuals will get ABBV-744 and oral navitoclax. In Segment D, individuals will acquire ABBV-744 and ruxolitinib. Participants will get treatment until eventually ailment progression or maybe the individuals are not able to tolerate the study drugs.Total, our recent work highlights the potential utilization of ARV-825 in combination